Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01).

@article{Charehbili2014AdditionOZ,
  title={Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01).},
  author={Ayoub Charehbili and Saskia van de Ven and Vincent T. H. B. M. Smit and Elma M Meershoek-Klein Kranenbarg and N A Hamdy and Hein Putter and Joan B. Heijns and Laurence J C van Warmerdam and Lisa Kessels and Marli Dercksen and Manon J A E Pepels and E. Schuuring Maartense and Hanneke W. M. van Laarhoven and Bianca Vriens and Martin N J M Wasser and A Elise van Leeuwen-Stok and Gerrit-Jan Liefers and Cornelis J. H. van de Velde and J. W. R. Nortier and J. R. Kroep},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2014},
  volume={25 5},
  pages={998-1004}
}
BACKGROUND The role of zoledronic acid (ZA) when added to the neoadjuvant treatment of breast cancer (BC) in enhancing the clinical and pathological response of tumors is unclear. The effect of ZA on the antitumor effect of neoadjuvant chemotherapy has not prospectively been studied before. PATIENTS AND METHODS NEOZOTAC is a national, multicenter… CONTINUE READING